NCT02519777: A reported trial by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02519777 |
|---|---|
| Title | A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification With Maraviroc and Dolutegravir With No Intensification or Intensification With Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | April 21, 2016 |
| Completion date | Dec. 2, 2019 |
| Required reporting date | Dec. 2, 2022, midnight |
| Actual reporting date | Dec. 17, 2021 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |